Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
Animals
Antigens, Neoplasm
/ genetics
Cancer Vaccines
/ administration & dosage
Clinical Trials, Phase I as Topic
Genetic Engineering
Humans
Immunogenicity, Vaccine
Immunotherapy
/ methods
Neoplasms
/ immunology
Salmonella typhimurium
/ genetics
Treatment Outcome
Tumor Microenvironment
/ immunology
Vaccines, Attenuated
/ administration & dosage
Xenograft Model Antitumor Assays
Bacteria-mediated cancer therapy
Cancer immunotherapy
Engineered Salmonella typhimurium
Tumor immune microenvironment
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
28 01 2020
28 01 2020
Historique:
received:
04
09
2019
revised:
29
09
2019
accepted:
21
10
2019
pubmed:
2
11
2019
medline:
1
7
2020
entrez:
1
11
2019
Statut:
ppublish
Résumé
Conventional chemotherapies have some limitations, including the lack of selectivity, high toxicity to normal tissues, multidrug resistance, and tumor relapse. Recently, great progress was made in immunotherapies for anticancer research, with bacteria-mediated cancer therapy one of the most promising approaches among them. Attenuated Salmonella have very specific targeting to various solid cancers, making them ideal vectors for the delivery and expression of immunostimulators. They have native bacterial immunogenicity and induce strong anticancer immunity in vivo. In this review, the recent advances in Salmonella-mediated cancer immunotherapies and the related mechanisms of Salmonella-based cancer therapies are summarized.
Identifiants
pubmed: 31666180
pii: S0304-3835(19)30536-1
doi: 10.1016/j.canlet.2019.10.033
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Cancer Vaccines
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102-110Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.